NA-Selank Amidate
N-Acetyl Selank Amidate · Enhanced Anxiolytic Nootropic
Enhanced form of Selank, the anxiolytic nootropic peptide out of Russia's Institute of Molecular Genetics. An N-acetyl group improves blood-brain barrier penetration and yields more stable metabolites, and C-terminal amidation adds further metabolic stability and receptor binding. Anxiety relief comes without the sedation, dependency, or cognitive impairment that attend benzodiazepines.
Overview
Enhanced form of Selank, the anxiolytic nootropic peptide out of Russia's Institute of Molecular Genetics. An N-acetyl group improves blood-brain barrier penetration and yields more stable metabolites, and C-terminal amidation adds further metabolic stability and receptor binding. Anxiety relief comes without the sedation, dependency, or cognitive impairment that attend benzodiazepines.
Several neurotransmitter systems — GABA, dopamine and serotonin among them — are modulated by NA-Selank Amidate, which also regulates brain-derived neurotrophic factor (BDNF). Modulation at GABAA receptors is allosteric and arrives without the sedation or dependency benzodiazepines bring. Serotonin metabolism in the hypothalamus and brainstem is activated, and BDNF levels rise, promoting neuronal growth and differentiation.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Memory trace stability increases for as long as 30 days in animal studies.
Learning and neuroplasticity are supported by elevated BDNF.
Where BDNF rises, the effects of neurological injury are reduced.
Russia approves standard Selank for GAD; delivery is enhanced in NA-Selank Amidate.
The stress response is modulated by way of GABA and serotonin systems, with no sedation.
Activated serotonin metabolism improves mood.
Built on the tuftsin structure, with immunomodulatory properties retained.
- Class
- Modified heptapeptide
- Research status
- Moderate research
- Chain length
- 7 residues
- Molecular weight
- 864 Da
- Half-life
- ~5 h
- Typical dose
- 200–500 µg per dose
- Frequency
- 1–2 times daily for 14–20 days
- Cycle length
- 2–3 weeks (14–20 days)
- Storage
- Refrigerate at 2-8°C
Molecular data
- Type
- Modified heptapeptide
- Molecular weight
- 864 Da
- Chain length
- 7 residues
- Half-life
- 300 min
Levels in single-dose multiples. A shape, not a pharmacokinetic prediction.
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Anxiety relief | Intranasal | 250-500 mcg | 1-2x daily |
| Cognitive enhancement | Intranasal | 200-400 mcg | 1-2x daily |
| Standard protocol | Intranasal | 300 mcg | 1-2x daily for 14 days |
| Alternative delivery | SubQ | 250-500 mcg | 1-2x daily |
Interactions
Combined often, giving comprehensive cognitive enhancement plus mood support.
The enhanced versions combine well, for effects both cognitive and anxiolytic.
Nootropic mechanisms differ; combination is possible.
No negative interaction reported.
What to expect
Safety
Mechanistic flags — properties of the pathway, not observed adverse events.
- Fatigue (rare)
- Tolerated well overall
- Nasal irritation, mild (intranasal)
- Allergic reactions
- Paradoxical anxiety increase
- Unusual mood changes
- Pregnancy or breastfeeding
- Known hypersensitivity, whether to Selank or tuftsin
- Severe psychiatric conditions (professional consultation indicated)
Quality checklist
What to confirm before trusting a batch of research material. A verification aid — not an endorsement of any supplier.
- Third-party Certificate of AnalysisIndependent lab · dated · lot-matched.
- HPLC purity ≥ 98%Reverse-phase trace included.
- Mass-spec confirms 864 g/molMALDI-TOF or ESI-MS.
- Counterion stated (acetate ≫ TFA)TFA salts can confound bioassays.
- Endotoxin / sterility statementRelevant once reconstituted.
- Lyophilised · cold-chain shippedStored −20 °C, shipped on ice.
- Labelled “research use only”No therapeutic or dosing claims.
Recorded signals for this compound · 7
- ✓Lyophilized powder, white to off-white
- ✓Solution clear once reconstituted
- ✓Vacuum seal intact
- !Slight clumping, dissolving readily
- ×Unusual odor
- ×Powder discolored
- ×Solution cloudy or with particles
FAQ
What separates NA-Selank Amidate from standard Selank?
Two modifications: acetylation at the N-terminus, amidation at the C-terminus. Blood-brain barrier penetration improves, metabolites come out more stable, and the half-life extends beyond that of standard Selank. Anxiolytic and cognitive effects are superior, with duration of action potentially longer.
Is continuous use of NA-Selank Amidate appropriate, with no breaks between cycles?
No. The protocol here limits cycles to 2–3 weeks, with breaks between them, to prevent potential GABAergic desensitization. Effectiveness may fall over time under continuous use without breaks, along the lines of the tolerance that develops with benzodiazepines — though no dependency has been reported for NA-Selank Amidate.
Is the intranasal route faster than injection for NA-Selank Amidate?
Yes. Direct access to the brain comes with the intranasal route, and onset is faster — 15–30 minutes — than by subcutaneous injection. Both routes are effective; the choice turns on convenience and bioavailability preferences.